LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Superficial Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Interventions

DRUG: EG-70 (phase 1)
DRUG: EG-70 (phase 2)

Sponsor

enGene, Inc.